Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals to $377 from $338 and keeps a Buy rating on the shares. The firm noted rezdiffra/resmetirom received FDA Accelerated Approval with a very clean label for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis, consistent with F2-F3 MASH; the first and only FDA-approved therapy for MASH.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals’ Rezdiffra™ Wins Accelerated FDA Approval
- Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
- Madrigal Pharmaceuticals price target raised to $405 from $275 at H.C. Wainwright
- Madrigal Pharmaceuticals price target raised to $338 from $336 at Canaccord
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
